Category: Tissue Regeneration
ProChon Biotech Ltd. says it's halfway home on its clinical trial of the BioCart knee cartilage treatment.
ProChon Biotech Ltd. says it will likely release the results from expanded clinical trials of its BioCart knee cartilage repair treatment by June.
The Woburn, Mass.-based company, which recently raised about $4 million in a convertible bridge loan to finance the trials, said it's about halfway through the patient enrollment process in the Phase II study and expects results to be released in three months.
ProChon is developing a system to repair damaged cartilage called the BioCart system, which uses proprietary fibroblast growth factor technology to help regenerate damaged cartilage in the knee.
Wound-healing startup CytoSolv Inc. lands $500,000 in seed money from Rhode Island's Slater Technology Fund to develop its treatment for diabetic ulcers.
Rhode Island's state-backed venture arm, the Slater Technology Fund, is investing $500,000 in Providence-based CytoSolv Inc., which is developing a treatment for diabetic ulcers and other wounds.
The company's technology is based on wound-healing factors derived from choroid plexus, part of the blood/brain barrier that secretes proteins involved in healing into the cerebrospinal fluid.
Serica Technologies Inc. becomes a wholly owned subsidiary of Irvine, Calif-based medical products giant Allergan.
Allergan Inc. (NYSE:AGN) acquired Serica Technologies Inc. for an undisclosed amount.
Medford, Mass.-based Serica, which is developing silk-based biomaterials for tissue repair, will become a wholly owned subsidiary of Irvine, Calif.-based Allergan, which makes products ranging from Botox to Lap-Band gastric banding systems.
Fall River, Mass.-based tissue regeneration firm NuOrtho Surgical Inc. hires former CR Bard R&D manager with deep ties to Johnson & Johnson as its new chief science officer.
NuOrtho Surgical Inc. added another former Johnson & Johnson (NYSE:JNJ) alum to its executive suite, naming Ian McRury as its new chief science officer.
McRury's most recent position was research and development manager for CR Bard Inc. (NYSE:BCR). He also spent nine years as a principal engineer for J&J's DePuy Mitek division in Raynham, Mass.
NuOrtho, which is headquartered in Fall River, Mass., is developing a device that uses radio frequencies to repair torn or frayed cartilage in the knee. The company has raised $2 million to date in two rounds of financing.
ProChon Biotech Ltd. closes a $4 million bridge loan from its holding company and the Musculoskeletal Transplant Foundation to fund an ongoing clinical trial and the manufacture of a key element of its BioCart knee cartilage repair system.
ProChon Biotech Ltd. closed a $3.95 million convertible bridge loan it plans to use to fund ongoing clinical trials and the manufacture of a key element of its BioCart knee repair system.
The Woburn, Mass.-based company, which is developing a system to repair damaged cartilage, said the loan came from prior backers ProChon Holdings B.V. and the Musculoskeletal Transplant Foundation. ProChon's BioCart system uses a proprietary fibroblast growth factor technology to help regenerate damaged cartilage in the knee.
InVivo Therapeutics Inc. settles its beef with Oregon Health & Science University, which it blamed for a botched primate study of its tissue regeneration technique for spinal cord injuries.
Attorneys for InVivo Therapeutics Inc. said the company has settled a lawsuit it filed against an Oregon research facility after a botched primate study last year.
Alexander Furey, the attorney for the Cambridge, Mass.-based tissue regeneration developer, told MassDevice that InVivo and Oregon Health & Sciences University reached a settlement. Furey declined to provide any specifics on the terms of the agreement, saying only that "the settlement was confidential."
Organogenesis Inc. filed a pre-market approval application with the Food & Drug Administration for its CelTx oral tissue regeneration product.
Organogenesis Inc. filed a pre-market approval application with the Food & Drug Administration for its CelTx oral tissue regeneration product.
The Canton, Mass.-based firm said the CelTx product is a living cellular construct designed to help heal the gums of patients with gingival recession. It's made of human fibroblasts, keratinocytes and extracellular matrix proteins.
